Risk factors for atherosclerosis and vascular calcification in patients with type 2 diabetes on long-term hemodialysis

Abstract

Type 2 diabetes mellitus (DM) is a risk factor for the progression of cardiovascular mortality, exacerbated by the development of chronic renal failure secondary to diabetic nephropathy, which requires long-term hemodialysis (LTH). However, in the case of LTH cardiovascular mortality exceeds that in the general population, especially in patients with diabetes. The identification of risk factors for the progression of atherosclerosis and vascular calcification in patients with DM on LTH is of great importance for finding a more effective approach to the prevention of cardiovascular mortality in a given cohort of patients. The presented review contains analysis of current literature data on the evaluation of both traditional and non-traditional risk factors for cardiovascular morbidity in order to improve the effectiveness of therapeutic and diagnostic tactics.

Keywords

Diabetes mellitus / vascular calcification / diabetic nephropathy / cardiovascular mortality / haemodialysis

References

[1] Consultant Doctor. Russian endocrinology clinical recommendations. Available from: http://www.rosmedlib.ru/book/ISBN9785970436837.html. [Last accessed on 24 Oct 2018] (in Russian)

[2] Foley RN,Parfrey PS,Kent GM.Cardiac disease in diabetic end-stage renal disease..Diabetologia1997;40:1307-12

[3] Tsujimoto T,Takahashi Y,Noto H.Asymptomatic coronary heart disease in patients with type 2 diabetes with vascular complications: a cross-sectional study..BMJ Open2011; PMCID:PMC3211053

[4] Stamler J,Neaton JD.Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial..Diabetes care1993;16:434-44

[5] Sarnak MJ,Schoolwerth AC,Culleton B.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention..Circulation2003;108:2154-69

[6] Dedov II. Results of the implementation of the subprogram “diabetes mellitus of the federal target program” prevention and control of socially significant diseases 2007-2012. Available from: https://cyberleninka.ru/article/n/rezultaty-realizatsii-podprogrammy-saharnyy-diabet-federalnoy-tselevoy-programmy-preduprezhdenie-i-borba-s-sotsialno-znachimymi. [Last accessed on 24 Oct 2018] (in Russian)

[7] Suzuki C,Ishibashi-Ueda H,Kawano Y.Evidence for severe atherosclerotic changes in chronic hemodialysis patients: comparative autopsy study against cardiovascular disease patients without chronic kidney disease..Ther Apher Dial2011;15:51-7

[8] Xue JL,Herzog CA.Association of heart disease with diabetes and hypertension in patients with ESRD..Am J Kidney Dis2005;45:316-23

[9] Go AS,Fan D,Hsu CY.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization..N Engl J Med2004;351:1296-305

[10] Tanaka M,Nagano K,Oe H.Moderate atheroma of the aortic arch and the risk of stroke..Cerebrovasc Dis2006;21:26-31

[11] Sen S,Lima J.Risk factors for progression of aortic atheroma in stroke and transient ischemic attack patients..Stroke2002;33:930-5

[12] Ku E.Is lipid management effective for all stages of CKD?.Blood Purif2013;35:26-30

[13] Bhowmik D.Metabolic syndrome and chronic kidney disease..Indian J Nephrol2008;18:1-4 PMCID:PMC2847722

[14] Kato A,Maruyama Y,Hishida A.Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients..Kidney Int2003;64:1472-9

[15] Gluba A,Paradowska A,Rysz J.The risk of atherosclerosis in patients with chronic kidney disease..Int Urol Nephrol2013;45:1605-12 PMCID:PMC3844144

[16] Vaziri ND.Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences..Am J Physiol Renal Physiol2006;290:F262-72

[17] Mutluay R,Poyraz F,Yücel C.Dialysis type may predict carotid intima media thickness and plaque presence in end-stage renal disease patients..Adv Ther2012;29:370-82

[18] Ragino YI.Oxidized and structurally-modified low-density lipoproteins in atherosclerosis..Atherosclerosis2006;2:3-32(in Russian)

[19] Stocker R.Role of oxidative modifications in atherosclerosis..Physiol Rev2004;84:1381-478

[20] Medical Theses. Mechanisms and role of atherogenic modification of lipoproteins in atherogenesis. Available from: http://medical-diss.com/medicina/mehanizmy-i-rol-aterogennoy-modifikatsii-lipoproteidov-v-aterogeneze. [Last accessed on 24 Oct 2018] (in Russian)

[21] Ylä-Herttuala S,Rosenfeld ME,Carew TE.Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man..J Clin Invest1989;84:1086-95 PMCID:PMC329764

[22] Belova LA,Belov AA.Processes of modification of lipoproteins. Physiological and pathogenetical role of modified lipoproteins..Vopr Med Khim2000;46:8-21(in Russian)

[23] Sukhorukov VN,Orekhov AN.Atherogenic modifications of low-density lipoproteins..Biomed Khim2016;62:391-402(in Russian)

[24] Lankin VZ,Tikhaze AK.The influence of glucose on the free radical peroxidation of low density lipoproteins in vitro and in vivo..Biomed Khim2012;58:339-52(in Russian)

[25] Borodachev EN,Karagodin VP,Orekhov A.Multiple modification of low density lipoproteins in diabetes..Pathogenesis2013;11:16-21(in Russian)

[26] Bucala R,Vega G,Koschinsky T.Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency..Proc Natl Acad Sci U S A1994;91:9441-5 PMCID:PMC44828

[27] Goodman WG,Kuizon BD,Gales B.Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis..N Engl J Med2000;342:1478-83

[28] Giachelli CM.Vascular calcification mechanisms..J Am Soc Nephrol2004;15:2959-64

[29] Volgina G,Balkarova O.Extrinsic calcification in patients with CKD..Vrach2012;7:2-8(in Russian)

[30] Rumberger JA,Fitzpatrick LA,Schwartz RS.Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study..Circulation1995;92:2157-62

[31] Ribeiro S,Brandão A,Guerra A.Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism..Nephrol Dial Transplant1998;13:2037-40

[32] Kalpakian MA.Vasgular calcification and disordered mineral metabolism in dialysis patients..Semin Dial2007;20:139-43

[33] Raggi P,Chasan-Taber S,Dillon M.Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?.J Am Coll Cardiol2002;39:695-701

[34] Bhan I.Vascular calcification and ESRD: a hard target..Clin J Am Soc Nephrol2009;

[35] Braun J,Moshage W,Zeitler E.Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients..Am J Kidney Dis1996;27:394-401

[36] Komaba H,Takashima M,Yokota K.Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines..Ther Apher Dial2008;12:42-8

[37] Bellasi A,Ratti C,Raggi P.Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients..J Nephrol2012;25:211-8

[38] Lee CT,Hsu CY,Ng HY.Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients..Dis Markers2013;34:229-35 PMCID:PMC3810241

[39] Volkov MM,Shevyakova EV. Factors associated with calcification of valvular heart apparatus in patients on chronic hemodialysis. Available from: https://cyberleninka.ru/article/n/faktory-svyazannye-s-kaltsinatsiey-klapannogo-apparata-serdtsa-u-patsientov-na-hronicheskom-gemodialize. [Last accessed on 24 Oct 2018] (in Russian)

[40] Cheng CY,Razzaque MS.Molecular regulation of phosphate metabolism by fibroblast growth factor-23- klotho system..Adv Chronic Kidney Dis2011;18:91-7 PMCID:PMC3120111

[41] Riminucci M,Fedarko NS,Corsi A.FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting..J Clin Invest2003;112:683-92 PMCID:PMC182207

[42] Shimada T,Yamazaki Y,Hino R.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis..J Bone Miner Res2004;19:429-35

[43] Volgina G,Balkarova O.Hyperphosphatemia in chronic kidney disease: modern correction strategy..Vrach2012;7:19-23(in Russian)

[44] Milovanova LY,Kozlovskaya LV.New markers of cardiorenal interrelations in chronic kidney disease..Therapeutic Archives2013;6:17-24(in Russian)

[45] Jean G,Vanel T,Lorriaux C.High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients..Nephrol Dial Transplant2009;24:2792-6

[46] Grabner A,Silswal N,Yanucil C.FGF23/FGFR4-mediated left ventricular hypertrophy is reversible..Sci Rep2017;7:1993 PMCID:PMC5434018

[47] Inaba M,Imanishi Y,Shioi A.Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients..Osteoporos Int2006;17:1506-13

[48] Chan GC,Russell GB,Wagenknecht LE.FGF23 concentration and APOL1 genotype are novel predictors of mortality in African Americans with type 2 diabetes..Diabetes Care2018;41:178-86 PMCID:PMC5741152

[49] Gutiérrez OM,Isakova T,Tamez H.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis..N Engl J Med2008;359:584-92 PMCID:PMC2890264

[50] Suliman ME,Bárány P,Anderstam B.Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus..Am J Kidney Dis2003;41:S89-95

[51] Kardami E,Jimenez SK,Sheikh F.Fibroblast growth factor 2 isoforms and cardiac hypertrophy..Cardiovasc Res2004;63:458-66

[52] Kestenbaum B,Rudser KD,Seliger SL.Serum phosphate levels and mortality risk among people with chronic kidney disease..J Am Soc Nephrol2005;16:520-8

[53] Munoz Mendoza J,Cai X,Faul C.Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease..Kidney Int2017;91:711-9 PMCID:PMC5313324

[54] Rahman A,Person SD,Kiefe C.Validity of self-reports of reasons for hospitalization by young adults and risk factors for discordance with medical records: the coronary artery risk development in young adults (CARDIA) study..Am J Epidemiol2005;162:491-8

[55] Coen G,Mantella D,Balducci A.Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?.Nephrol Dial Transplant2007;22:3262-7

[56] Giachelli CM.Vascular calcification mechanisms..J Am Soc Nephrol2004;15:2959-64

[57] Freedman BI,Russell GB,Bowden DW.Plasma FGF23 and calcified atherosclerotic plaque in african americans with type 2 diabetes mellitus..Am J Nephrol2015;42:391-401 PMCID:PMC4732898

[58] Lanzer P,Sorribas V,Janzen J.Medial vascular calcification revisited: review and perspectives..Eur Heart J2014;35:1515-25 PMCID:PMC4072893

[59] Ishimura E,Kitatani K,Shoji T.Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients--importance of glycaemic control..Diabetologia2002;45:1446-8

[60] Combe C,Asano Y,Maroni BJ.Kidney disease outcomes quality initiative (K/DOQI) and the dialysis outcomes and practice patterns study (DOPPS): nutrition guidelines, indicators, and practices..Am J Kidney Dis2004;44:39-46

[61] Titan SM,Graciolli FG,Barros RT.FGF-23 as a predictor of renal outcome in diabetic nephropathy..Clin J Am Soc Nephrol.2011;6:241-7 PMCID:PMC3052212

[62] Palmer SC,Macaskill P,Craig JC.Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis..JAMA2011;305:1119-27

[63] Qu W,Azen SP,Wong ND.Value of coronary artery calcium scanning by computed tomography for predicting coronary heart disease in diabetic subjects..Diabetes Care2003;26:905-10